Company: NCEL
Filing Date: 2025-06-16
Form Type: 425
Source: 0001213900-25-054487
Chunk: 4

Company: NewcelX Ltd.
Filing Date: 2025-06-16
Form: 425
Chunk 4
---
 on the Tel Aviv Stock Exchange
(TASE: KDST).

Social Media: LinkedIn,
X, Facebook, Instagram

Safe Harbor Statement

This press release contains expressed or implied
forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements
when they discuss the expected closing, and the timing of the closing, of the transaction and the potential benefits of the transaction
to NLS and Kadimastem and their respective shareholders, including value creation for shareholders, as well as the expected strategic
position of the combined company following the Merger, if completed, and the plan to prepare and initiate a Phase IIa multi-site clinical
trial of AstroRx®, Kadimastem’s product candidate for Amyotrophic Lateral Sclerosis (ALS). These forward-looking statements
and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following
factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks related
to the companies’ ability to complete the Merger on the proposed terms and schedule, including risks and uncertainties related to
the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely,
or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses resulting from the transaction and
potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Merger; changes
in technology and market requirements; either or both companies may encounter delays or obstacles in launching and/or successfully completing
their clinical trials; the companies’ products may not be approved by regulatory agencies; their technologies may not be validated
as they progress and their methods may not be accepted by the scientific community; either of both of the companies may be unable to retain
or attract key employees whose knowledge is essential to the development of their products; unforeseen scientific difficulties may develop
with the products being advanced by the companies; their products may wind up being more expensive than anticipated; results in the laboratory
may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results
of human clinical trials; the companies’ patents may not be sufficient; their products may harm recipients; changes in legislation
may adversely impact either or both of the